CNS Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CNS Pharmaceuticals, Inc. (CNSP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.00K, a 90.91% decline year-over-year.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.00K, a 95.16% decline year-over-year.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $18.45K, a 93.21% decline year-over-year.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $22.00K, a 90.61% decline year-over-year.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $187.73K, a 77.62% decline from fiscal 2024.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $838.96K, a 16.72% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.01M, a 16.26% decline from fiscal 2022.
- CNS Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.20M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.00K 10-Q · filed 2026-08-12 | $5.00K derived: sum of 2 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $3.00K 10-Q · filed 2026-08-12 | $2.56K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $187.73K 10-K · filed 2026-03-31 | ||||
| 2025-09-30 | $18.45K 10-Q · filed 2025-11-14 | $40.45K derived: sum of 2 quarters · filed 2026-08-12 | $102.45K derived: sum of 3 quarters · filed 2026-08-12 | ||
| 2025-06-30 | $22.00K 10-Q · filed 2026-08-12 | $21.84K 10-Q · filed 2025-08-14 | $84.00K derived: sum of 2 quarters · filed 2026-08-12 | ||
| 2025-03-31 | $62.00K 10-Q · filed 2026-08-12 | $62.37K 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $838.96K 10-K · filed 2026-03-31 | ||||
| 2024-09-30 | $271.78K 10-Q · filed 2025-11-14 | $506.12K derived: sum of 2 quarters · filed 2025-11-14 | $709.06K derived: sum of 3 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $234.34K 10-Q · filed 2025-11-14 | $437.28K derived: sum of 2 quarters · filed 2025-11-14 | |||
| 2024-03-31 | $202.93K 10-Q · filed 2025-11-14 | ||||
| 2023-12-31 | $1.01M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $194.76K 10-Q · filed 2024-11-14 | $484.43K derived: sum of 2 quarters · filed 2024-11-14 | $774.74K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $289.67K 10-Q · filed 2024-11-14 | $579.98K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $290.31K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | $1.20M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $289.72K 10-Q · filed 2023-11-14 | $576.56K derived: sum of 2 quarters · filed 2023-11-14 | $913.25K derived: sum of 3 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $286.84K 10-Q · filed 2023-11-14 | $623.53K derived: sum of 2 quarters · filed 2023-11-14 | |||
| 2022-03-31 | $336.69K 10-Q · filed 2023-11-14 | ||||
| 2020-12-31 | $362.95K derived: 10-K 12 month − 3 quarters · filed 2021-02-12 | $727.96K derived: sum of 2 quarters · filed 2021-02-12 | $1.05M derived: sum of 3 quarters · filed 2021-02-12 | $1.29M 10-K · filed 2021-02-12 | |
| 2020-09-30 | $365.01K 10-Q · filed 2020-11-12 | $688.23K derived: sum of 2 quarters · filed 2020-11-12 | $930.44K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2020-06-30 | $323.22K 10-Q · filed 2020-11-12 | $565.43K derived: sum of 2 quarters · filed 2020-11-12 | |||
| 2020-03-31 | $242.21K 10-Q · filed 2020-11-12 | ||||
| 2019-12-31 | $477.10K 10-K · filed 2021-02-12 | ||||
| 2019-09-30 | $172.92K 10-Q · filed 2020-11-12 | $242.76K derived: sum of 2 quarters · filed 2020-11-12 | $286.78K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $69.84K 10-Q · filed 2020-11-12 | $113.86K derived: sum of 2 quarters · filed 2020-11-12 | |||
| 2019-03-31 | $44.02K 10-Q · filed 2020-11-12 | ||||
| 2018-12-31 | $102.74K 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $44.02K 10-Q · filed 2019-12-20 | $53.53K derived: sum of 2 quarters · filed 2019-12-20 | $58.72K derived: sum of 3 quarters · filed 2019-12-20 | ||
| 2018-06-30 | $9.51K 10-Q · filed 2019-12-20 | $14.71K derived: sum of 2 quarters · filed 2019-12-20 | |||
| 2018-03-31 | $5.20K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |